662-Hypoimmune CD19 CAR T Cells Evade Allorejection

This research report evaluates the SC291 hypoimmune (HIP) CD19 CAR T cell product, an allogeneic therapy engineered to treat cancers and autoimmune diseases without triggering patient rejection. By utilizing CRISPR-Cas editing to remove HLA markers and overexpress CD47, these specialized cells successfully bypassed both innate and adaptive immune responses in clinical trial participants. The study...去小宇宙查看完整单集简介
前往小宇宙评论区与主播互动